Shionogi &. 

$19.93
56
-$0.92-4.41%Monday 15:52

Statistics

Day High
20.85
Day Low
20.85
52W High
26
52W Low
15.21
Volume
100
Avg. Volume
70
Mkt Cap
17.73B
P/E Ratio
11.95
Dividend Yield
2.7%
Dividend
0.54

Upcoming

Dividends

2.7%Dividend Yield
Dec 2026
$0.25
Jun 2026
$0.23
Dec 2025
$0.21
Jun 2025
$0.23
Dec 2024
$0.57
10Y Growth
34.35%
5Y Growth
5.98%
3Y Growth
11.47%
1Y Growth
-43.74%

Earnings

Feb 5Expected
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Q3 2026
Next
0.16
0.34
0.52
0.71
Expected EPS
0.40967736168
Actual EPS
N/A

Financials

41.03%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
3.27BRevenue
1.34BNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SGIOF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap164.67B
Pfizer is a global pharmaceutical company that competes with Shionogi in various therapeutic areas, including infectious diseases and vaccines.
Merck
MRK
Mkt Cap364.26B
Merck & Co. is a direct competitor in the pharmaceutical sector, particularly in the fields of infectious diseases and oncology, areas where Shionogi also operates.
GSK
GSK
Mkt Cap101.13B
GlaxoSmithKline competes with Shionogi in the development and marketing of medications for infectious diseases, including HIV and respiratory infections.
Johnson & Johnson
JNJ
Mkt Cap687.89B
Johnson & Johnson, through its pharmaceutical division Janssen, competes in areas such as infectious diseases and mental health, overlapping with Shionogi's portfolio.
Abbvie
ABBV
Mkt Cap521.5B
AbbVie competes with Shionogi in the pharmaceutical market, particularly in areas like virology, where both companies have significant investments.
Novartis
NVS
Mkt Cap303.12B
Novartis is a global healthcare company that competes with Shionogi in multiple therapeutic areas, including neuroscience and cardiovascular diseases.
Astrazeneca
AZN
Mkt Cap286.07B
AstraZeneca competes with Shionogi in areas such as infectious diseases and oncology, with both companies investing in research and development for new treatments.
Sanofi
SNY
Mkt Cap116.15B
Sanofi competes with Shionogi in the global pharmaceutical market, particularly in areas like vaccines and infectious diseases.
Bristol-Myers Squibb
BMY
Mkt Cap129.66B
Bristol Myers Squibb is a competitor in the pharmaceutical industry, focusing on areas like oncology and cardiovascular diseases, which are also of interest to Shionogi.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG competes with Shionogi in the pharmaceutical and diagnostics sectors, particularly in oncology and infectious diseases.

About

Shionogi & Co., Ltd., an Osaka, Japan-based pharmaceutical company established in 1878, focuses on the discovery, development, production, and commercialization of medicines, diagnostic tools, and medical devices primarily within Japan. The company, known as Shionogi Shoten Co., Ltd. until its rebranding in 1943, maintains a comprehensive portfolio. Its marketed products include Fetroja, an agent for multidrug-resistant gram-negative bacterial infections; Xofluza, an antiviral treatment for influenza; and Tivicay, utilized in HIV therapy. Shionogi's extensive pipeline features investigational therapies such as Symproic for opioid-induced constipation; S-120083 for inflammatory pain and S-010887 for neuropathic pain; S-117957 for insomnia; sivopixant, addressing neuropathic pain, sleep apnea syndrome, and persistent chronic cough; S-637880 for neuropathic low back pain; Zuranolone for depression; SDT-001 for attention-deficit/hyperactivity disorder; BPN14770 for Fragile X syndrome and Alzheimer's disease; and S-237648 and S-309309 for obesity. Further development initiatives encompass ADR-001 for decompensated liver cirrhosis; S-723595 for NASH; various oncology candidates including S-588410 for esophageal and bladder cancer, S-488210 for head and neck squamous cell carcinoma, S-588210 for solid tumors, S-222611 for malignant tumors, and S-531011 for solid tumors; S-770108 for idiopathic pulmonary fibrosis; SR-0379 for cutaneous ulcers; S-005151 for stroke and epidermolysis bullosa; S-0373 for spinocerebellar ataxia; and multiple compounds targeting COVID-19, such as S-600918, S-217622, and S-555739 for mitigating disease progression. Additionally, the firm offers antibody test kits for COVID-19. Shionogi fosters strategic alliances, including collaborations with Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University, aimed at advancing antimalarial drug research.
Show More
CEO
Isao Teshirogi
Employees
6223
Country
Japan
ISIN
JP3347200002
WKN
000855648

Listings

0 Comments

Share your thoughts

FAQs

What is Shionogi &. stock price today?▼
The current price of SGIOF is $19.93 USD — it has decreased by -4.41% in the past 24 hours. Watch Shionogi &. stock price performance more closely on the chart.
What is Shionogi &. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Shionogi &. stocks are traded under the ticker SGIOF.
Is Shionogi &. stock price growing?▼
SGIOF stock has risen by +2.78% compared to the previous week, the month change is a +10.72% rise, over the last year Shionogi &. has showed a +13.89% increase.
What is Shionogi &. market cap?▼
Today Shionogi &. has the market capitalization of 17.73B
When is the next Shionogi &. earnings date?▼
Shionogi &. is going to release the next earnings report on February 5, 2027.
What were Shionogi &. earnings last quarter?▼
SGIOF earnings for the last quarter are 0.16 USD per share, whereas the estimation was 0.28 USD resulting in a -41.16% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Shionogi &. revenue for the last year?▼
Shionogi &. revenue for the last year amounts to 3.27B USD.
What is Shionogi &. net income for the last year?▼
SGIOF net income for the last year is 1.34B USD.
Does Shionogi &. pay dividends?▼
Yes, SGIOF dividends are paid semi-annual. The last dividend per share was 0.23 . As of today, Dividend Yield (FWD)% is 2.7%.
How many employees does Shionogi &. have?▼
As of November 17, 2026, the company has 6,223 employees.
In which sector is Shionogi &. located?▼
Shionogi &. operates in the Health & Wellness sector.
When did Shionogi &. complete a stock split?▼
The last stock split for Shionogi &. was on September 27, 2024 with a ratio of 3:1.
Where is Shionogi &. headquartered?▼
Shionogi &. is headquartered in Kita, Japan.